STAT
FEBRUARY 15, 2024
More than 100,000 doctors have left private practice and become employees of hospitals and other corporate entities since 2019. Today, nearly three in four physicians are employees of larger health care entities or other corporations — a record high. As an independent physician, I know exactly why so many are making that choice.
The Pharmacist
FEBRUARY 15, 2024
Almost two-thirds (62%) of Covid-19 vaccines were administered in community pharmacies in December 2023, according to the Company Chemists’ Association (CCA). The CCA’s analysis, based on data from NHS England and Freedom of Information requests, found that community pharmacy had administered more than 40 million Covid-19 vaccinations by the end of 2023 – a quarter […] The post Quarter of all Covid vaccines administered in community pharmacies appeared first on The Pharmacist.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
STAT
FEBRUARY 15, 2024
WASHINGTON — A new trove of internal emails and other documents from the e-cigarette maker Juul reveals the company’s extensive behind-the-scenes efforts to promote its interests in Washington — a rare insight into the otherwise opaque methods corporations use to influence the government. It’s well documented that Juul spent significant sums on registered lobbyists and political donations back in 2018 and 2019, when the head of the Food and Drug Administration declare
BioPharma Dive
FEBRUARY 15, 2024
Analysts pressed Alnylam executives on the reasons for the changes to HELIOS-B, a Phase 3 study in ATTR amyloidosis with cardiomyopathy that is important to the company’s future.
Speaker: Chris Antypas and Josh Halladay
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
STAT
FEBRUARY 15, 2024
A new report released Thursday by the Centers for Disease Control and Prevention appears to show that Lyme disease cases in the United States rose by 69% in 2022 over previous years. But in reality, the sharp increase is likely due to a new way of doing surveillance for the disease, not an explosion of cases. The change, an attempt to lift a crushing reporting burden off the shoulders of states where Lyme disease infections are common, went into effect in 2022.
PharmaVoice
FEBRUARY 15, 2024
Researchers are unleashing the powers of AI for precision medicine, drug development and more.
Pharmacist Digest brings together the best content for pharmacists from the widest variety of industry thought leaders.
Putting Patients First Blog
FEBRUARY 15, 2024
Guest Post: February is Marfan Awareness Month! February 15, 2024 By: April Dawn Shinske, Chief Communications and Marketing Officer, The Marfan Foundation During Marfan Awareness Month 2024, members of the community living with Marfan syndrome — a genetic aortic and vascular condition that impacts connective tissue — have been sharing their diverse perspectives through short videos called #marfanrealreels.
STAT
FEBRUARY 15, 2024
With the Supreme Court just a month away from hearing arguments over access to the abortion medication mifepristone, a new study published on Wednesday in Nature Medicine offers additional evidence that abortion pills are safe to prescribe — even remotely. Researchers looked at the records of more than 6,000 patients who received medication abortion — a combination of mifepristone and misoprostol — through pills delivered via mail after a telehealth consultation conducted in
pharmaphorum
FEBRUARY 15, 2024
The HHS provides guidance on using online tracking technologies in a HIPAA-compliant manner. Learn how to ensure your analytics practices align with healthcare regulations and protect patient privacy.
STAT
FEBRUARY 15, 2024
The Food and Drug Administration is cracking down on websites that claim to sell the underlying chemicals of popular diabetes and obesity drugs like Ozempic, Wegovy, and Zepbound, saying that the websites are selling unapproved and misbranded drug products. The regulator this week posted warning letters that it sent to two websites, Synthetix Inc. DBA Helix Chemical Supply and US Chem Labs.
Advertisement
Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.
Pulses
FEBRUARY 15, 2024
By: Morgan Lewis PharmD Candidate, Sara Stallworth PharmD, and Jeff Cain EdD, MS Introduction Nestled in library corners, pharmacy students sit hunched over desks, meticulously poring over their class notes, portraying a picture-perfect scene of “traditional studying.” Yet this romanticized version of studying may not be the best for learning. Students often use i nput-based study strategies , which can involve reading notes or rewatching video recordings, which have a goal of “cementing” the in
STAT
FEBRUARY 15, 2024
For several years , some of the world’s largest pharmaceutical companies that participate in a U.S. drug discount program overcharged the federal government and numerous hospitals by hundreds of millions of dollars, according to claims made in a recently unsealed lawsuit. The allegations, which were made by Adventist Health System, turn on the complicated, behind-the-scenes calculations used to provide medicines to what is known as the 340B program.
Drug Patent Watch
FEBRUARY 15, 2024
Elevate your excipient business strategies with the comprehensive Drug Excipient Business Development Reports from DrugPatentWatch. Designed for excipient manufacturers seeking lucrative opportunities in the pharmaceutical industry, these reports offer invaluable… The post Drug Excipient Business Development Reports now Available on Amazon appeared first on DrugPatentWatch - Make Better Decisions.
STAT
FEBRUARY 15, 2024
You’re reading the web edition of STAT’s Health Tech newsletter, our guide to how technology is transforming the life sciences. Sign up to get it delivered in your inbox every Tuesday and Thursday. Remote patient monitoring coding reforms tabled again Earlier this month, an American Medical Association -anointed panel was set to consider proposed changes that would have simplified and broadened applicability of billing codes governing wearables and other devices d
pharmaphorum
FEBRUARY 15, 2024
Healthtech specialist Innsena has committed funding and expertise to CancerX, launched last year to encourage the use of digital health technologies to overcome challenges in cancer care.
STAT
FEBRUARY 15, 2024
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Hello, everyone. Damian here with a look at a complicatedly important ALS study, biotech’s latest volatility, and some green shoots for a downtrodden part of the industry.
Pharmaceutical Technology
FEBRUARY 15, 2024
The success of recent trials treating mental health problems with psychedelic therapies has driven a rapid rise in investment in the area.
STAT
FEBRUARY 15, 2024
This week, a preview of the TUDCA study in ALS and thoughts on how it might impact Amylyx Pharmaceuticals. Also, I chatted with CRISPR Therapeutics CEO Sam Kulkarni about its new investor. Read to the end for some burning questions, random thoughts. The next ALS data readout — overdue but important A European academic consortium is expected to announce results soon from a clinical trial investigating the use of a widely available nutritional supplement called tauroursodeoxycholic acid, or
pharmaphorum
FEBRUARY 15, 2024
Exercise matched psychotherapy and was more effective than medication as a treatment for #depression in a meta-analysis of randomised clinical trials
STAT
FEBRUARY 15, 2024
Has PhRMA lost its fangs? Are 11th-hour changes ominous for clinical trials? And what’s next in pain medicine? We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. The pharmaceutical industry, in court and in Congress, is working to water down legislation that will let Medicare negotiate certain drug prices.
Pharmaceutical Commerce
FEBRUARY 15, 2024
Patients with severe frostbite who were administered Aurlumyn monotherapy experienced a significantly reduced risk of the need for amputation.
STAT
FEBRUARY 15, 2024
Struggling to breathe, the patient stepped out of the registration line in the hospital’s overwhelmed emergency department to find help. Her chest hurt, she told the triage nurse on duty that evening at Brockton’s Good Samaritan Medical Center. The nurse, backed up with more than a dozen waiting patients, thought it was anxiety and told her to get back in line.
pharmaphorum
FEBRUARY 15, 2024
Gene-editing biotech Prime Medicine has priced an initial public offering, hoping to raise $140 million to advance its pipeline of one-shot therapies for severe genetic disorders. The Cambridge, Massachusetts-based company is offering 19.2 million shares at $6.25 each and expects to start trading on the Nasdaq on 20th February under the PRME symbol.
STAT
FEBRUARY 15, 2024
Top of the morning to you, and a fine one it is. Clear blue skies are enveloping the Pharmalot campus this morning, where the official mascots continue to enjoy the tundra-like grounds and we are brewing yet another cup of stimulation. Our choice today, for those who track this sort of thing, is bananas Foster. As always, you are welcome to join us.
Pharma Times
FEBRUARY 15, 2024
CLM-HT01 improved blood pressure and minimised adverse reactions in patients
PharmaVoice
FEBRUARY 15, 2024
A disappointing few years for Biogen have led leadership to use new drug launches as fuel for an about-face.
Pharma Times
FEBRUARY 15, 2024
In Europe, stroke-related brain-bleed deaths are expected to increase by 8.
The Pharmacist
FEBRUARY 15, 2024
The government will continue exploring whether HIV prevention drug Pre-Exposure Prophylaxis (PrEP) could be made available in settings other than sexual health services (SHSs), including community pharmacies, it has said in a roadmap published today. This will include a roundtable convened by the Department of Health and Social Care (DHSC) in 2024-25 to consider available […] The post ‘More evidence’ needed on providing PrEP in pharmacies appeared first on The Pharmacist.
European Pharmaceutical Review
FEBRUARY 15, 2024
A clinical trial in malignant pleural mesothelioma (MPM) has demonstrated the first successful combination of chemotherapy with a drug targeting cancer’s metabolism developed for the asbestos-induced disease in two decades. The anti-cancer treatment combines the new drug ADI-PEG20 and traditional chemotherapy. The Phase III ATOMIC-meso trial was led by Queen Mary University of London in the UK and studied 249 patients with the disease.
Pharmaceutical Technology
FEBRUARY 15, 2024
As the market is progressively becoming saturated by GLP-1 receptor agonists, companies are investigating alternative mechanisms of action.
European Pharmaceutical Review
FEBRUARY 15, 2024
The investment… includes state-of-the-art instrumentation to provide full CMC support to serve the growth of PODP [manufacturers]” Nelson Labs, a global leader in microbiological and analytical chemistry testing and advisory services for the medical device and pharmaceutical industries has announced its Itasca, Illinois laboratory in the US as a new Pharmaceutical Center of Excellence to serve the unique needs of parenteral and ophthalmic drug product (PODP) manufacturers.
World Pharma News
FEBRUARY 15, 2024
Bayer AG and Asklepios BioPharmaceutical, Inc. (AskBio), a gene therapy company wholly owned and independently operated as a subsidiary of Bayer AG, announced that the first patient has been randomized in GenePHIT (Gene PHosphatase Inhibition Therapy), a Phase II trial of AB-1002 (also known as NAN-101) for the treatment of congestive heart failure (CHF).
pharmaphorum
FEBRUARY 15, 2024
The FTC is investigating wholesalers and other middlemen in the pharma supply chain to assess their possible role in worsening shortages of generic medicines
Pharmaceutical Technology
FEBRUARY 15, 2024
The US FDA has granted approval for Eicos Sciences' Aurlumyn for adults with severe frostbite to lower the risk of amputation.
Outsourcing Pharma
FEBRUARY 15, 2024
Artax Biopharma, a clinical-stage biotech company focused on transforming the treatment of autoimmune diseases, has dosed the first patient in its phase 2a trial evaluating oral, small molecule, AX-158 for the treatment of psoriasis.
Expert insights. Personalized for you.
362 
Let's personalize your content